<p><em>与 Milestone Pharmaceuticals 共同开发的 PSVT 新型治疗方案</em></p>
<p>伊利诺伊州水晶湖 --（商业资讯）--Aptar Group, Inc.（纽约证券交易所代码：ATR），全球药物和消费品剂量、分配和保护技术的领导者，今天宣布其双剂量（BDS）液体鼻用喷雾系统是新批准的 CARDAMYST™（etripamil）鼻用喷雾的给药机制。CARDAMYST 已获得美国食品和药物管理局（FDA）的批准，用于将成人阵发性室上性心动过速（PSVT）的急性症状发作转化为窦性心律。这种新型治疗方案由 Milestone® Pharmaceuticals Inc.（纳斯达克代码：MIST）开发，该生物制药公司专注于创新心血管药物的开发和商业化。这标志着 Aptar 首次将双剂量给药系统结合在一个消费者友好的保护双包装容器中。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20251217190273/en/2673472/4/Cardamyst_Case_Product_Dec_2025_-_2.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20251217190273/en/2673472/4/Cardamyst_Case_Product_Dec_2025_-_2.jpg"/></p>
<p>Milestone Pharmaceuticals 获得美国食品和药物管理局对 CARDAMYST 的批准，用于将成人阵发性室上性心动过速（PSVT，通常称为 SVT）的急性症状发作转化为窦性心律。</p>
<p>估计目前美国有两百万人被诊断为 PSVT，这是一种心律失常或异常心律。PSVT 的特点是突然出现的快速心跳，通常超过每分钟 150 到 200 次，导致每年在美国约有 140,000 到 525,000 次急诊就诊和 40,000 到 120,000 次住院治疗。</p>
<p>集成双剂量设备容器封闭系统确保可靠的药物获取。CARDAMYST 易于使用，体积小巧，方便患者按指示携带使用。Aptar CSP Technologies 与 Milestone Pharmaceuticals 合作开发了一种定制设计的、患者友好的聚丙烯容器封闭系统，配备了完全集成的瓶盖，用于 CARDAMYST。该保护性双容器系统旨在安全地容纳两个双剂量给药机制，具有防止意外激活或从容器掉落的功能，并有助于在需要时提高可靠性。</p>
<p>Aptar Pharma 总裁 Gael Touya 表示：“这一批准强调了 Aptar 在更多治疗领域扩展药物给药解决方案的能力，以及对鼻用药物给药日益增长的需求。我们很高兴我们的双剂量鼻用系统与我们的保护双容器系统结合，现在可以为患者提供另一种治疗方案。”</p>
<p>Aptar Pharma 处方业务总裁 Alex Theodorakis 补充道：“经过与 Milestone 多年的紧密合作，这一成功结果再次证明了我们支持全球客户开发和推出复杂治疗方案的能力，提供易于使用和可靠的系统。”</p>
<p>“Aptar 在开发和提供一种填补严重未满足需求的 PSVT 新型治疗方案方面是一个重要合作伙伴。我们为与一家共享创新和质量承诺的公司合作而感到自豪，并期待共同为患者提供 CARDAMYST，” Milestone Pharmaceuticals 总裁兼首席执行官 Joseph Oliveto 说道。</p>
<p><strong>经过验证的鼻用药物给药平台</strong></p>
<p>Aptar 的双剂量（BDS）和单剂量（UDS）系统旨在实现直观、可靠的鼻内给药，并满足严格的美国 FDA 质量标准。提供有效且经过验证的单次或双次鼻内给药，适用于多种药物，这些平台支持制药合作伙伴开发紧急使用治疗方案。</p>
<p><strong>通过 Aptar Pharma 服务加速开发支持</strong></p>
<p>这种针对 PSVT 的创新治疗方案是组合产品提交的另一个例子，并受益于 Aptar Pharma 的药物服务提供，这是一系列特定阶段的开发套餐。Aptar 的专职监管事务专家和分析科学家帮助客户主动应对监管需求，以加快批准进程。</p>
<p><strong>关于 Aptar</strong></p>
<p>Aptar 是药物和消费品剂量、分配和保护技术的全球领导者。Aptar 服务于多个有吸引力的终端市场，包括制药、美容、食品、饮料、个人护理和家庭护理。利用市场专业知识、专有设计、工程和科学，为许多世界领先品牌创造创新解决方案，Aptar 在全球数百万患者和消费者的生活、外观、健康和家庭中产生了重要影响。Aptar 总部位于伊利诺伊州水晶湖，在 20 个国家拥有超过 13,000 名专职员工。有关更多信息，请访问 www.aptar.com。</p>
<p><strong>关于 Milestone Pharmaceuticals</strong></p>
<p>Milestone Pharmaceuticals Inc.（纳斯达克代码：MIST）是一家生物制药公司，致力于开发和商业化创新心血管药物，以造福患有某些心脏疾病的人群。Milestone 的主要产品是 CARDAMYST™（etripamil）鼻用喷雾，这是一种新型钙通道阻滞剂，已获得 FDA 批准，用于将成人阵发性室上性心动过速（PSVT）的急性症状发作转化为窦性心律。Etripamil 还在开发中，用于治疗与快速心室率相关的房颤症状性发作，或称 AFib-RVR。www.milestonepharma.com</p>
<p>本新闻稿包含前瞻性声明，包括关于 Aptar 的 Bidose 鼻用系统在递送 CARDAMYST 方面预期的好处和表现、预期的患者使用和采纳、未来市场机会，以及我们在将鼻用药物递送解决方案扩展到其他治疗领域方面的计划。前瞻性声明通常可以通过其不严格与历史或当前事实相关联的事实以及使用 “期望”、“预期”、“相信”、“估计”、“未来”、“潜在”、“持续” 等词语或 “将”、“应该”、“会” 和 “可能” 等未来或条件动词来识别。前瞻性声明是根据 1933 年证券法第 27A 条和 1934 年证券交易法第 21E 条的安全港条款作出的，并基于我们的信念以及我们当前可获得的信息和假设。因此，由于我们运营和商业环境中存在的已知或未知的风险和不确定性，我们的实际结果或其他事件可能与这些前瞻性声明中表达或暗示的内容有重大差异，包括但不限于：CARDAMYST 的成功商业化和市场接受度；我们支持客户开发和推出药物 - 设备组合产品的能力；监管要求和合规性；以及竞争，包括技术进步。有关这些及其他风险和不确定性的更多信息，请参见我们向证券交易委员会提交的文件，包括我们 10-K 和 10-Q 表格中的 “风险因素” 和 “管理层对财务状况和经营结果的讨论与分析” 部分。我们没有义务公开更新任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，法律要求的除外。</p>
<p><strong>1</strong> PSVT - 关注领域 - Milestone Pharma</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTcxOTAyNzNyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTcxOTAyNzNyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251217190273/en/</p>
<p><strong>Aptar 投资者关系联系人：</strong></p>
<p>Mary Skafidas</p>
<p>mary.skafidas@aptar.com</p>
<p>+1 347 351 6407</p>
<p><strong>Aptar 制药媒体联系人：</strong></p>
<p>Ciara Jackson</p>
<p>ciara.jackson@aptar.com</p>
<p>+49 151 1951 6502</p>
<p><strong>Aptar 媒体联系人：</strong></p>
<p>Katie Reardon</p>
<p>katie.reardon@aptar.com</p>
<p>+1 815 479 5671</p>
<p>来源：Aptar Group, Inc.</p>

阿普达

<p>Aptar 集团的 Bidose 鼻用喷雾系统正在提供 CARDAMYST™（etripamil），这是首个获得 FDA 批准的自我给药鼻用喷雾剂，用于阵发性室上性心动过速（PSVT）。CARDAMYST 与 Milestone Pharmaceuticals 共同开发，旨在将急性 PSVT 发作转化为成人的窦性心律。该产品采用双重 Bidose 给药系统，配备保护容器，确保可靠性和易用性。这一批准突显了 Aptar 在鼻用药物递送解决方案方面的扩展，以及与 Milestone 的合作，以满足未被满足的医疗需求</p>

<p><em>Novel treatment for PSVT developed with Milestone Pharmaceuticals</em></p>
<div class="lb-trans"><p><em>与 Milestone Pharmaceuticals 共同开发的 PSVT 新型治疗方案</em></p>
</div><p>CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) Liquid Nasal Spray System is the mechanism for delivering the newly approved CARDAMYST™ (etripamil) Nasal Spray. CARDAMYST received approval by the U.S. Food and Drug Administration (FDA) for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The novel treatment was developed by Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. This marks Aptar’s first combination of dual Bidose delivery systems housed in a consumer-friendly protective two-pack container.</p>
<div class="lb-trans"><p>伊利诺伊州水晶湖 --（商业资讯）--Aptar Group, Inc.（纽约证券交易所代码：ATR），全球药物和消费品剂量、分配和保护技术的领导者，今天宣布其双剂量（BDS）液体鼻用喷雾系统是新批准的 CARDAMYST™（etripamil）鼻用喷雾的给药机制。CARDAMYST 已获得美国食品和药物管理局（FDA）的批准，用于将成人阵发性室上性心动过速（PSVT）的急性症状发作转化为窦性心律。这种新型治疗方案由 Milestone® Pharmaceuticals Inc.（纳斯达克代码：MIST）开发，该生物制药公司专注于创新心血管药物的开发和商业化。这标志着 Aptar 首次将双剂量给药系统结合在一个消费者友好的保护双包装容器中。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20251217190273/en/2673472/4/Cardamyst_Case_Product_Dec_2025_-_2.jpg" alt="" original-src="https://mms.businesswire.com/media/20251217190273/en/2673472/4/Cardamyst_Case_Product_Dec_2025_-_2.jpg"/></p>
<p>Milestone Pharmaceuticals received U.S. Food and Drug Administration approval of CARDAMYST for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT), commonly called SVT, to sinus rhythm in adults.</p>
<div class="lb-trans"><p>Milestone Pharmaceuticals 获得美国食品和药物管理局对 CARDAMYST 的批准，用于将成人阵发性室上性心动过速（PSVT，通常称为 SVT）的急性症状发作转化为窦性心律。</p>
</div><p>An estimated two million people in the United States are currently diagnosed with PSVT, a type of arrhythmia or abnormal heart rhythm. PSVT is characterized by episodes of sudden onset rapid heartbeats often exceeding 150 to 200 beats per minute, resulting in an estimated 140,000 to 525,000 Emergency Department visits and 40,000 to 120,000 inpatient hospitalizations in the U.S. each year1.</p>
<div class="lb-trans"><p>估计目前美国有两百万人被诊断为 PSVT，这是一种心律失常或异常心律。PSVT 的特点是突然出现的快速心跳，通常超过每分钟 150 到 200 次，导致每年在美国约有 140,000 到 525,000 次急诊就诊和 40,000 到 120,000 次住院治疗。</p>
</div><p>Integrated Bidose Device Container Closure System Ensures Reliable Drug Access CARDAMYST is easy to use and is small enough to be conveniently carried by patients for use as directed. Aptar CSP Technologies collaborated with Milestone Pharmaceuticals to develop a custom-designed, patient-friendly polypropylene container closure system with a fully integrated cap for CARDAMYST. This protective dual-container system is designed to securely house two Bidose delivery mechanisms, with features intended to prevent accidental activation or dropping from the container and help promote reliability at the moment of need.</p>
<div class="lb-trans"><p>集成双剂量设备容器封闭系统确保可靠的药物获取。CARDAMYST 易于使用，体积小巧，方便患者按指示携带使用。Aptar CSP Technologies 与 Milestone Pharmaceuticals 合作开发了一种定制设计的、患者友好的聚丙烯容器封闭系统，配备了完全集成的瓶盖，用于 CARDAMYST。该保护性双容器系统旨在安全地容纳两个双剂量给药机制，具有防止意外激活或从容器掉落的功能，并有助于在需要时提高可靠性。</p>
</div><p>Gael Touya, President of Aptar Pharma, said, “This approval underscores the broadening of Aptar’s drug delivery solutions for more therapeutic areas and the growing demand for nasal drug delivery. We are pleased that our trusted and proven Bidose nasal system, combined with our protective dual-container system, is now available for patients in yet another therapeutic area.”</p>
<div class="lb-trans"><p>Aptar Pharma 总裁 Gael Touya 表示：“这一批准强调了 Aptar 在更多治疗领域扩展药物给药解决方案的能力，以及对鼻用药物给药日益增长的需求。我们很高兴我们的双剂量鼻用系统与我们的保护双容器系统结合，现在可以为患者提供另一种治疗方案。”</p>
</div><p>Alex Theodorakis, President, Aptar Pharma Prescription, added, “After years of close collaboration with Milestone, this successful outcome proves again our capability to support customers globally to develop and launch complex treatments with easy-to-use and reliable systems.”</p>
<div class="lb-trans"><p>Aptar Pharma 处方业务总裁 Alex Theodorakis 补充道：“经过与 Milestone 多年的紧密合作，这一成功结果再次证明了我们支持全球客户开发和推出复杂治疗方案的能力，提供易于使用和可靠的系统。”</p>
</div><p>“Aptar has been an essential partner in developing and delivering a novel treatment for PSVT that fills a serious unmet need. We are proud to partner with a company that shares our commitment to innovation and quality and look forward to working together to provide CARDAMYST to patients,” said Joseph Oliveto, President and CEO, Milestone Pharmaceuticals.</p>
<div class="lb-trans"><p>“Aptar 在开发和提供一种填补严重未满足需求的 PSVT 新型治疗方案方面是一个重要合作伙伴。我们为与一家共享创新和质量承诺的公司合作而感到自豪，并期待共同为患者提供 CARDAMYST，” Milestone Pharmaceuticals 总裁兼首席执行官 Joseph Oliveto 说道。</p>
</div><p><strong>Proven Nasal Drug Delivery Platforms</strong></p>
<div class="lb-trans"><p><strong>经过验证的鼻用药物给药平台</strong></p>
</div><p>Aptar’s Bidose (BDS) and Unidose (UDS) systems are designed for intuitive, reliable intranasal administration and for meeting strict U.S. FDA quality standards. Offering effective and proven single or two-shot intranasal delivery for a variety of medicines, these platforms support pharmaceutical partners in developing emergency use treatments.</p>
<div class="lb-trans"><p>Aptar 的双剂量（BDS）和单剂量（UDS）系统旨在实现直观、可靠的鼻内给药，并满足严格的美国 FDA 质量标准。提供有效且经过验证的单次或双次鼻内给药，适用于多种药物，这些平台支持制药合作伙伴开发紧急使用治疗方案。</p>
</div><p><strong>Accelerated Development Support via Aptar Pharma Services</strong></p>
<div class="lb-trans"><p><strong>通过 Aptar Pharma 服务加速开发支持</strong></p>
</div><p>This innovative treatment for PSVT is another example of a Combination Product submission, and benefited from Aptar Pharma’s Drug Services offering, a comprehensive portfolio of stage-specific development packages. Aptar’s dedicated Regulatory Affairs experts and analytical scientists help customers proactively address regulatory needs to help expedite approval.</p>
<div class="lb-trans"><p>这种针对 PSVT 的创新治疗方案是组合产品提交的另一个例子，并受益于 Aptar Pharma 的药物服务提供，这是一系列特定阶段的开发套餐。Aptar 的专职监管事务专家和分析科学家帮助客户主动应对监管需求，以加快批准进程。</p>
</div><p><strong>About Aptar</strong></p>
<div class="lb-trans"><p><strong>关于 Aptar</strong></p>
</div><p>Aptar is a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science to create innovative solutions for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.</p>
<div class="lb-trans"><p>Aptar 是药物和消费品剂量、分配和保护技术的全球领导者。Aptar 服务于多个有吸引力的终端市场，包括制药、美容、食品、饮料、个人护理和家庭护理。利用市场专业知识、专有设计、工程和科学，为许多世界领先品牌创造创新解决方案，Aptar 在全球数百万患者和消费者的生活、外观、健康和家庭中产生了重要影响。Aptar 总部位于伊利诺伊州水晶湖，在 20 个国家拥有超过 13,000 名专职员工。有关更多信息，请访问 www.aptar.com。</p>
</div><p><strong>About Milestone Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>关于 Milestone Pharmaceuticals</strong></p>
</div><p>Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST™ (etripamil) nasal spray, a novel calcium channel blocker, which is FDA approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in development for the treatment of symptomatic episodic attacks associated with atrial fibrillation with rapid ventricular rate, or AFib-RVR. www.milestonepharma.com</p>
<div class="lb-trans"><p>Milestone Pharmaceuticals Inc.（纳斯达克代码：MIST）是一家生物制药公司，致力于开发和商业化创新心血管药物，以造福患有某些心脏疾病的人群。Milestone 的主要产品是 CARDAMYST™（etripamil）鼻用喷雾，这是一种新型钙通道阻滞剂，已获得 FDA 批准，用于将成人阵发性室上性心动过速（PSVT）的急性症状发作转化为窦性心律。Etripamil 还在开发中，用于治疗与快速心室率相关的房颤症状性发作，或称 AFib-RVR。www.milestonepharma.com</p>
</div><p><em>This press release contains forward-looking statements, including regarding the anticipated benefits and performance of Aptar’s Bidose Nasal System in delivering CARDAMYST, expected patient use and adoption, future market opportunities, and our plans with respect to expanding nasal drug delivery solutions into additional therapeutic areas. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by use of words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: the successful commercialization and market acceptance of CARDAMYST; our ability to support customers in the development and launch of drug-device combination products; regulatory requirements and compliance; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K and Form 10-Qs. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</em></p>
<div class="lb-trans"><p>本新闻稿包含前瞻性声明，包括关于 Aptar 的 Bidose 鼻用系统在递送 CARDAMYST 方面预期的好处和表现、预期的患者使用和采纳、未来市场机会，以及我们在将鼻用药物递送解决方案扩展到其他治疗领域方面的计划。前瞻性声明通常可以通过其不严格与历史或当前事实相关联的事实以及使用 “期望”、“预期”、“相信”、“估计”、“未来”、“潜在”、“持续” 等词语或 “将”、“应该”、“会” 和 “可能” 等未来或条件动词来识别。前瞻性声明是根据 1933 年证券法第 27A 条和 1934 年证券交易法第 21E 条的安全港条款作出的，并基于我们的信念以及我们当前可获得的信息和假设。因此，由于我们运营和商业环境中存在的已知或未知的风险和不确定性，我们的实际结果或其他事件可能与这些前瞻性声明中表达或暗示的内容有重大差异，包括但不限于：CARDAMYST 的成功商业化和市场接受度；我们支持客户开发和推出药物 - 设备组合产品的能力；监管要求和合规性；以及竞争，包括技术进步。有关这些及其他风险和不确定性的更多信息，请参见我们向证券交易委员会提交的文件，包括我们 10-K 和 10-Q 表格中的 “风险因素” 和 “管理层对财务状况和经营结果的讨论与分析” 部分。我们没有义务公开更新任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，法律要求的除外。</p>
</div><p><em><strong>1</strong></em> <em>PSVT - Areas of Focus - Milestone Pharma</em></p>
<div class="lb-trans"><p><strong>1</strong> PSVT - 关注领域 - Milestone Pharma</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTcxOTAyNzNyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251217190273r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251217190273/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251217190273/en/</p>
</div><p><strong>Aptar Investors Relations Contact:</strong></p>
<div class="lb-trans"><p><strong>Aptar 投资者关系联系人：</strong></p>
</div><p>Mary Skafidas</p>
<div class="lb-trans"><p>Mary Skafidas</p>
</div><p>mary.skafidas@aptar.com</p>
<div class="lb-trans"><p>mary.skafidas@aptar.com</p>
</div><p>+1 347 351 6407</p>
<div class="lb-trans"><p>+1 347 351 6407</p>
</div><p><strong>Aptar Pharma Media Contact:</strong></p>
<div class="lb-trans"><p><strong>Aptar 制药媒体联系人：</strong></p>
</div><p>Ciara Jackson</p>
<div class="lb-trans"><p>Ciara Jackson</p>
</div><p>ciara.jackson@aptar.com</p>
<div class="lb-trans"><p>ciara.jackson@aptar.com</p>
</div><p>+49 151 1951 6502</p>
<div class="lb-trans"><p>+49 151 1951 6502</p>
</div><p><strong>Aptar Media Contact:</strong></p>
<div class="lb-trans"><p><strong>Aptar 媒体联系人：</strong></p>
</div><p>Katie Reardon</p>
<div class="lb-trans"><p>Katie Reardon</p>
</div><p>katie.reardon@aptar.com</p>
<div class="lb-trans"><p>katie.reardon@aptar.com</p>
</div><p>+1 815 479 5671</p>
<div class="lb-trans"><p>+1 815 479 5671</p>
</div><p>Source: Aptar Group, Inc.</p>
<div class="lb-trans"><p>来源：Aptar Group, Inc.</p>
</div>

Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT) | ATR Stock News

阿普达的双剂量鼻用系统提供 CARDAMYST™（依曲帕米），这是首个也是唯一一个自我管理的 FDA 批准的用于阵发性室上性心动过速（PSVT）的鼻喷剂 | ATR 股票新闻